Abstract
Due to the proliferation of new SARS-CoV-2 variants, most COVID-19 cases are now caused by post-vaccine infections and a substantial proportion are reinfections. While prior research on correlates of protection has focused on the role of anti-spike antibodies, the results of the corresponding antibody assays may not accurately predict the risk of infection with new SARS-CoV-2 variants. In this study, we investigated the association between live virus neutralising antibody activity and SARS-CoV-2 infection risk using self-administered capillary microsample blood tests from VirusWatch participants. The study was conducted during the transition between the dominance of the B.1.617.2 (Delta) and B.1.1.529 (Omicron BA.1) SARS-CoV-2 variants, enabling us to investigate the association between variant-specific virus inhibition and subsequent infections within each dominance period. Greater inhibition of Omicron BA.1 live virus was associated with a reduction in infection risk during both the Delta and Omicron BA.1 dominance periods. Delta virus inhibition was associated with infection risk reduction during the Delta dominance period, but we found no association between Delta inhibition and protection against infection during the Omicron BA.1 dominance period. Our results are consistent with earlier findings and suggest that variant-specific serosurveillance of immunity and protection against SARS-CoV-2 infection at the population level could inform public health policy in near-real time using inexpensive and accessible home-based testing.
Competing Interest Statement
ACH serves on the UK New and Emerging Respiratory Virus Threats Advisory Group.
Funding Statement
This work was supported by the Medical Research Council [Grant Ref: MC_PC 19070] awarded to UCL on 30 March 2020 and the Medical Research Council [Grant Ref: MR/V028375/1] awarded on 17 August 2020. The study also received $15,000 of advertising credit from Facebook to support a pilot social media recruitment campaign on 18th August 2020. The antibody testing undertaken by the vaccine evaluation subcohort was supported by funding from the Department of Health and Social Care from Feb 2021 - March 2022. This study was supported by the Wellcome Trust through a Wellcome Clinical Research Career Development Fellowship to RWA [206602]. IB is supported by an NIHR Academic Clinical Fellowship. SB and TB were supported by an MRC doctoral studentship (MR/N013867/1). The study sponsor(s) had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Virus Watch study adheres to all relevant ethical regulations and the study protocol has been approved by the Hampstead NHS Health Research Authority Ethics Committee (ethics approval number - 20/HRA/2320).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes